Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

A comprehensive meta-analysis of 18 studies, involving more than 1 million patients with autoimmune diseases, has revealed a 36% higher risk of central nervous system (CNS) inflammatory diseases in ...

Demyelinating diseases are any conditions that damage the protective coating on nerve cells, the myelin sheath. Some common demyelinating diseases of the central nervous system include multiple ...

Inhibiting an immune signaling protein called TLR7 may help preserve the protective layer surrounding nerve fibers in the brain during both Alzheimer's disease and ordinary aging, suggests a study led ...

A preclinical study by biomedical scientists at the University of California, Riverside, has shown why some people with multiple sclerosis, or MS, also suffer from seizures—a debilitating complication ...

Teriflunomide treatment incurred an unadjusted risk reduction of 63% and an adjusted risk reduction of 72% in inhibiting a first clinical demyelinating event in patients with multiple sclerosis (MS).

Learn how pain is managed in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), including medications, therapies, procedures, and lifestyle strategies.

In the human central nervous system, there are tiny cells that—for most people, most of the time—provide important immune protection to the brain and spinal cord. Occasionally these microglia cells ...

Demyelination occurs when the protective covering of nerve fibers in the brain, spinal cord, and optic nerves, known as myelin, is damaged. This myelin sheath facilitates the rapid transmission of ...

When Ozgun Gokce was a child, his family’s television broke. Losing that TV prompted him to figure out why it went kaput. That initial curiosity led Gokce into a career of understanding why things ...